This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (28)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Vera B. Morhenn, MD; Kathryn Pregerson-Rodan, MD; Renata Henzl Mullen, MD; Gary S. Wood, MD; Brian J. Nickoloff, MD, PhD; Stephen A. Sherwin, MD; Eugene M. Farber, MD

Arch Dermatol. 1987;123(12):1633-1637.

Abstract
• Twenty-three patients with chronic plaque-type psoriasis were treated with intramuscular administration of human recombinant interferon gamma. Patients were treated with doses of 0.01 to 0.25 mg/m² daily (five out of seven days) for four weeks, or 0.25 mg/m² three times weekly for one week with escalation to 0.5 mg/m² for the subsequent seven weeks. Some patients treated with the 0.25-mg/m² dose showed improvement coincident with their therapy. Although recombinant interferon gamma may have some therapeutic activity in certain patients' psoriasis, the magnitude of this effect is at best small. This result is in contrast to interferon alfa, which has been reported to cause an exacerbation of this disease. Staining of posttreatment biopsy specimens with a monoclonal antibody against HLA-DR antigen using an immunoperoxidase technique demonstrated HLA-DR expression by keratinocytes in some of the patients treated at the higher doses. No obvious correlation was seen between clinical improvement of the psoriasis and intensity or extent of HLA-DR antigen expression by keratinocytes in the skin biopsy specimens.

(Arch Dermatol 1987;123:1633-1637)

Author Affiliations
From the Department of Dermatology, Stanford (Calif) University (Drs Morhenn, Pregerson-Rodan, Mullen, Wood, and Nickoloff); Genentech Inc, South San Francisco, Calif (Dr Sherwin); and the Psoriasis Research Institute, Palo Alto, Calif (Dr Farber).

Footnotes
Accepted for publication June 19, 1987.

Presented in part at the national meeting of the Society for Investigative Dermatology, Washington, DC, May 2, 1986.

Reprints not available.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Psoriatic keratinocytes show reduced IRF-1 and STAT-1{alpha} activation in response to {gamma}-IFN
JACKSON et al.
FASEB J. 1999;13:495-502.
ABSTRACT | FULL TEXT  

The Cytokine Network in Psoriasis
Nickoloff
Arch Dermatol 1991;127:871-884.
ABSTRACT  

Psoriasis Induced at the Injection Site of Recombinant Interferon Gamma: Results of Immunohistologic Investigations
Fierlbeck et al.
Arch Dermatol 1990;126:351-355.
ABSTRACT  

Recombinant Interferon Gamma in Psoriasis
Schulze and Mahrle
Arch Dermatol 1988;124:487-488.
ABSTRACT